Object
Title: Synthesis of novel amide and hydrazide purine-2,6-dione and benzimidazole derivatives as TRPA1 channel antagonists with potential analgesic and anti-inflammatory activity
Abstract:
The treatment of chronic pain, e.g. neuropathic pain with currently available analgesics is not fully effective. Moreover, these drugs possess numerous side effects and have the potential to lead dependence. The search for safe and non-addictive analgesics with a new mechanism of action is one of the challenges of modern pharmacotherapy. TRPA1 channel antagonists that blocking the pain peripherally are considered one of the promising strategy for the treatment of neuropathic pain. The aim of the present thesis was to design and synthesize novel amide and hydrazide derivatives of 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione and 1H-benzimidazole, and to determine their antagonistic activity against the TRPA1 channel in vitro. Compounds with this mechanism of action may be effective in the treatment of chronic pain, including neuropathic pain and inflammatory conditions. A library of 135 compounds belonging to the amide and hydrazide derivatives of 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione 7˗26 (series Ia) and 123˗134 (series Ib) and 8-amino- and 8-alkoxy-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione 51˗78 (series IIa), 93˗119 (series IIIa), 136˗139 (series IIb) and 141˗143 (series IIIb), as well as 1H-benzimidazole 150˗170 (series IVa) and 181˗192 (series IVb) and 2-piperydyno-1H-benzimidazole 174˗177 (series Va) and 194˗197 (series Vb) was designed by structural modification o ; f HC-030031 ˗ the model TRPA1 channel antagonist and drug-likeness analysis in silico. The designed new compounds were obtained by multi-step procedure, using classical chemical methods, and microwave-assisted synthesis. In the first step, intermediate esters were obtained, followed by acids and hydrazides. In the final step, the condensation reaction with amines or aldehydes took place, respectively leading to the final N-phenylamides (series Ia˗Va) and N'-benzylidenohydrazides (series Ib˗Vb). The identity of the new final products and intermediates was confirmed by spectral (1H NMR) and for the compounds 93, 94, 97, 98, 101, 102, 105˗107, 109˗117 by elemental analysis. Molecular weights were verified by UPLC/MS. The purity of the obtained compounds was determined using the UPLC/MS technique. For the all 135 novel compounds, the antagonistic activity of the TRPA1 channel was determined using a fluorometric calcium imaging assay and HEK-293 cells stably expressing human TRPA1 channel. The biological tests in vitro allowed to select from the series of tested compounds the potent TRPA1 channel antagonists, with better antagonistic activity than that of HC-030031. Analysis of the structure-activity relationship (SAR) in the search groups of 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione and 1H-benzimidazole derivatives allowed to determine the influence of structural elements on the ; antagonistic activity of the TRPA1 channel. Among others, the length of the aliphatic chain and its branching, the type of substituent in the amide and hydrazide moieties, introduction of an additional amino or alkoxy substituent, and replacement of 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione with a 1H-benzimidazole system were assessed. For representative novel TRPA1 channel antagonists from the group of amide (compounds 94 and 102; series IIIa) and hydrazide (compounds 142 and 143; series IIIb) derivatives of 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione, a potential binding mode to the TRPA1 ion channel was determined using molecular modeling. The obtained results allowed to draw conclusions regarding the structural requirements for this class of antagonists, ensuring optimal binding with this biological target. Based on the results of in vitro tests, the most promising compounds 94 and 102, with stronger antagonistic activity than the HC-030031 were selected for in vivo pharmacological study in order to confirm the analgesic and anti-inflammatory properties. In the second (inflammatory) phase of the formalin test, compounds 94 and 102 showed stronger analgesic activity than that of HC-030031. Compounds 94 and 102 revealed antiallodynic properties in oxaliplatin-induced neuropathic pain model. In the von Frey test, the analgesic activity of the tested compounds was compara ; ble or weaker than that of pregabalin, used as a positive control, while in the cold plate test it was higher than that of pregabalin. Both evaluated compounds also showed more potent anti-inflammatory properties than HC-030031 in the carrageenan-induced edema model. Compound 102 possessed comparable activity to ketoprofen (positive control), the effect of compound 94 was weaker than reference drug. The findings of this study confirmed that the presented novel TRPA1 channel antagonists are promising for the treatment of chronic pain, including neuropathic pain and inflammatory conditions.
Place of publishing:
Level of degree:
Degree discipline:
Degree grantor:
Rada Dyscypliny Nauki farmaceutyczne
Promoter:
Date issued:
Identifier:
Call number:
Language:
Access rights:
Object collections:
Last modified:
Jun 20, 2024
In our library since:
Mar 2, 2023
Number of object content hits:
0
Number of object content views in PDF format
0
All available object's versions:
http://dl.cm-uj.krakow.pl:8080/publication/4963
Show description in RDF format:
Show description in OAI-PMH format:
| Edition name | Date |
|---|---|
| ZB-136281 | Jun 20, 2024 |
Objects
Similar
Ślusarczyk, Marietta Teresa
Lipkowska, Anna
Grzywacz-Kisielewska, Agata
Jarosz, Magdalena
Baran, Marzena
Sołtys, Agnieszka Beata
Kocot-Kępska, Magdalena
Jagła, Grzegorz
